{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:22:10Z","timestamp":1790702530782,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Viral infections can promote cytokine storm and multiorgan failure in individuals with an underlying immunosuppression or specific genetic background. Hyperinflammatory states, including critical forms of COVID-19, are characterized by a remodeling of the lipid profile including a dramatic decrease of the serum levels of apolipoprotein-A-I (ApoA-I), a protein known for its capacity to reduce systemic and lung inflammation, modulate innate and adaptive immunity, and prevent endothelial dysfunction and blood coagulation. In this study, four immunocompromised patients with severe COVID-19 cytokine storm that progressed despite standard-of-care therapy [Omicron (<jats:italic>n<\/jats:italic> = 3) and Delta (<jats:italic>n<\/jats:italic> = 1) variants] received 2\u2013 4 infusions (10\u00a0mg\/kg) of CER-001, an ApoA-I-containing HDL mimetic. Injections were well-tolerated with no serious adverse events. Three patients treated while not on mechanical ventilation had early clinical and biological improvement (oxygen withdrawal and correction of hematological and inflammatory parameters, including serum levels of interleukin-8) and were discharged from the hospital 3\u20134\u00a0days after CER-001 infusions. In the fourth patient who received CER-001 after orotracheal intubation for acute respiratory distress syndrome, infusions were followed by transient respiratory improvement before secondary worsening related to ventilation-associated pneumonia. This pilot uncontrolled exploratory compassionate study provides initial safety and proof-of-concept data from patients with a COVID-19 cytokine storm receiving ApoA-I. Further randomized controlled trial evaluation is now required to ascertain whether ApoA-I has any beneficial effects on patients with a COVID-19 cytokine storm.<\/jats:p>","DOI":"10.3389\/fphar.2022.936659","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T05:57:50Z","timestamp":1664171870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study"],"prefix":"10.3389","volume":"13","author":[{"given":"Stanislas","family":"Faguer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Del Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Danet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Renaudineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Izopet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in \u223c1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/s41598-021-81638-1","article-title":"Altered high-density lipoprotein composition and functions during severe COVID-19","volume":"11","author":"Begue","year":"2021","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"eabj7521","DOI":"10.1126\/scitranslmed.abj7521","article-title":"Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort","volume":"14","author":"Carapito","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/antiox10020209","article-title":"Native high-density lipoproteins (HDL) with higher paraoxonase exerts a potent antiviral effect against SARS-CoV-2 (COVID-19), while glycated HDL lost the antiviral activity","volume":"10","author":"Cho","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0197420","DOI":"10.1128\/JVI.01974-20","article-title":"ApoA1 neutralizes proinflammatory effects of dengue virus NS1 protein and modulates viral immune evasion","volume":"95","author":"Coelho","year":"2021","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"del Valle","year":"2020","journal-title":"Nat. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ccc.2022.02.001","article-title":"COVID-19 acute respiratory distress syndrome: One pathogen, multiple phenotypes","volume":"38","author":"Empson","year":"2022","journal-title":"Crit. Care Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.7326\/L20-1300","article-title":"Administration of the high-density lipoprotein mimetic CER-001 for inherited lecithin-cholesterol acyltransferase deficiency","volume":"174","author":"Faguer","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study","volume":"10","author":"Gangneux","year":"2022","journal-title":"Lancet. Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1651-2227.1991.tb11928.x","article-title":"Lipoprotein alterations and plasma lipoprotein lipase reduction in familial hemophagocytic lymphohistiocytosis","volume":"80","author":"Henter","year":"1991","journal-title":"Acta Paediatr. Scand."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.jlr.2021.100061","article-title":"Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection","volume":"62","author":"Hilser","year":"2021","journal-title":"J. Lipid Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/blood.v97.8.2381","article-title":"Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes","volume":"97","author":"Hyka","year":"2001","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1080\/21505594.2021.1964329","article-title":"The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells","volume":"12","author":"Kelesidis","year":"2021","journal-title":"Virulence"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/art.41763","article-title":"Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers","volume":"73","author":"Kessel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40261-017-0506-3","article-title":"Development of CER-001 : Preclinical dose selection through to phase I clinical findings","volume":"37","author":"Keyserling","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.bbrc.2005.10.065","article-title":"Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation","volume":"338","author":"Kim","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e241222","DOI":"10.1136\/bcr-2020-241222","article-title":"Case of haemophagocytic lymphohistiocytosis following Epstein-Barr virus infection","volume":"14","author":"Kraskovsky","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0214245","DOI":"10.1371\/journal.pone.0214245","article-title":"Inflammatory status and severity of disease in dengue patients are associated with lipoprotein alterations","volume":"14","author":"Marin-Palma","year":"2019","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","article-title":"Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: A randomized clinical trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e13661","DOI":"10.1111\/eci.13661","article-title":"SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1","volume":"51","author":"Pagano","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"eabm5505","DOI":"10.1126\/sciimmunol.abm5505","article-title":"Innate immunological pathways in COVID-19 pathogenesis","volume":"7","author":"Paludan","year":"2022","journal-title":"Sci. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0242306","DOI":"10.1371\/journal.pone.0242306","article-title":"Performance of serum apolipoprotein-A1 as a sentinel of Covid-19","volume":"15","author":"Poynard","year":"2020","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1152\/ajpcell.00467.2009","article-title":"Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages","volume":"298","author":"Smythies","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1096\/fj.202001451","article-title":"COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches","volume":"34","author":"Sorokin","year":"2020","journal-title":"FASEB J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/0042-6822(90)90229-k","article-title":"Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs","volume":"176","author":"Srinivas","year":"1990","journal-title":"Virology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"584987","DOI":"10.3389\/fcvm.2020.584987","article-title":"Lipid profile features and their associations with disease severity and mortality in patients with COVID-19","volume":"7","author":"Sun","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/biomedicines10040754","article-title":"First recombinant high-density lipoprotein particles administration in a severe ICU COVID-19 patient, a multi-omics exploratory investigation","volume":"10","author":"Tanaka","year":"2022","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/01.cir.0000030182.35880.3e","article-title":"Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide","volume":"106","author":"van Lenten","year":"2002","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1161\/01.CIR.0000147232.75456.B3","article-title":"D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.","volume":"110","author":"van Lenten","year":"2004","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202109-2150OC","article-title":"Vasculopathy and increased vascular congestion in fatal COVID-19 and ARDS","author":"Villalba","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.936659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T05:57:52Z","timestamp":1664171872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.936659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.936659"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.936659","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"936659"}}